Kavya Reddy: "Indian biotech doesn't need permission from Boston anymore"

Kavya Reddy trained at Stanford. She did a postdoc at Broad. By the standard career arc, she should have stayed in Boston, joined a US biotech, and written her name on a series of US-headquartered patents.

Instead she went home. Helix Bio, the gene therapy company she founded in 2022, is headquartered in Bangalore, with a small wet lab in Hyderabad and a clinical operations team in Mumbai. None of its sixty-four employees are based in the United States.

The decision was — and Reddy is candid about this — controversial within her own scientific network.

"I had peers telling me directly that I was making a career-limiting choice," she said. "They were genuinely concerned. The model they had for what biotech success looked like ran through Cambridge or Kendall Square. I was breaking the model."

The thesis

Reddy's reasoning was straightforward. The diseases she most cared about — particularly inherited blood disorders highly prevalent in South Asian populations — were systematically under-resourced by US biotech because the patient populations didn't generate the kind of revenue that US-listed biotech companies needed to justify their valuations.

"You can't build a $30 billion company addressing a disease that affects three million people in a country where the average treatment cost has to be $4,000 for the math to work. Boston wasn't going to fund what I wanted to build. So I had to build the funding model somewhere else."

That somewhere else turned out to be a mix of Indian family office capital, two Indian government-backed deep-science funds, and — eventually — US venture firms that had figured out that the cost-of-development advantage of running clinical operations out of India was real and durable.

The economics

The economic argument Reddy makes is uncomfortable for the US biotech industry. Helix Bio's per-trial costs, by her account, are roughly 40% lower than equivalent US trials, with — she insists — equivalent clinical rigor. The regulatory pathway through CDSCO, India's drug regulator, has matured significantly in the past five years; the bar is now broadly comparable to the FDA for most rare-disease pathways.

That cost advantage, combined with patient populations large enough to actually run trials at speed, is what allows Helix to address diseases US companies can't.

"This isn't a charity argument. The economics are better here. The patient populations are larger. The talent is excellent. The capital is now real. The only thing we've been missing is the willingness to acknowledge that the model is competitive."

The Series B

Helix recently closed a $60 million Series B led by an Indian sovereign-linked fund, with participation from two US healthcare-focused VC firms and an Asian sovereign wealth fund. The round, covered in our funding section, values the company at roughly $310 million.

The strategic implication, Reddy said, is that Helix can now run multiple clinical programs in parallel — something the company has been capital-constrained from doing.

"The thing about gene therapy is that you can't be a single-product company. The platform has to address multiple targets. We've had three programs in the lab waiting for capital. Now they get to be funded."

For more on Indian biotech and our emerging-markets coverage, see those sections.